Table 2.
Marker characteristics of analyzed tumors (N = 103)
| Marker | n (%) | |
|---|---|---|
| ER, n (%) | Positive | 101 (98.1) |
| Negative | 2 (1.9) | |
| PgR, n (%) | Positive | 98 (95.1) |
| Negative | 3 (4.9) | |
| HER2, n (%) | Positive | 7 (6.8) |
| Negative | 96 (93.2) | |
| AR, n (%) | Positive | 99 (96.1) |
| Negative | 4 (3.9) | |
| PD-L1, n (%) | IC0 | 96 (93.2) |
| IC1 | 6 (5.8) | |
| IC2 | 1 (1.0) | |
| sTILs, n (%) | 0–10% | 80 (77.7) |
| 10–20% | 17 (16.5) | |
| 20–30% | 4 (3.9) | |
| 30–40% | 2 (1.9) | |
| Ki-67, mean (SD) | 17.55 (18.17) |
IHC immunohistochemistry, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor 2, AR androgen receptor, PD-L1 programmed death-ligand 1, sTILs stromal tumor-infiltrating lymphocytes, SD standard deviation